glp 1 cardiovascular benefit Bridging the gap between GLP1-receptor agonists and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Frontiers | Glucagon-like peptide-1 receptor

Mounjaro metabolic benefits Tirzepatide consistently demonstrates improvements across multiple metabolic markers: Blood sugar control: HbA1c reductions of 1.87% to 2.07% in type 2 diabetes trials Blood pressure: Modest systolic blood pressure reductions of 4-7 mmHg Lipids: Improvements in triglycerides and cholesterol profiles Waist circumference: Significant reductions correlating with visceral fat loss Inflammatory markers: Reductions in high-sensitivity C-reactive protein These benefits make tirzepatide more than just a weight loss drug

Although liraglutide, semaglutide, and tirzepatide have become the predominant GLP-1 RAs for obesity management, exenatide remains a clinically relevant option, particularly for older adults managing both obesity and T2DM [70]

The Healthy Weight Loss module is designed specifically for patients with clinical obesity (Rubino et al., 2023) who are motivated to pursue healthy and sustainable weight loss

Advances in biological therapy for the management of arthritis

Drug coverage works through layers of approval

However, the researchers concluded that liraglutide was not associated with the occurrence of SSIBs